Clinical trial
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
NCT00385125 · University of Magdeburg, Other · Unknown status
Key facts
| NCT number | NCT00385125 |
|---|---|
| Title | Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL |
| Official title | Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. |
| Lead sponsor | University of Magdeburg, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, High-Grade |
| Intervention type | Drug |
| Interventions | Bendamustine, Rituximab |
| Enrollment | 30 |
| Start date | Aug 1, 2004 |
| Completion | Aug 1, 2010 |
| First posted | Oct 6, 2006 |
| Last update posted | Oct 6, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: